At the beginning of September, Jiudian Pharmaceutical's Vildagliptin tablets were successfully approved for marketing by NMPA and passed the generic drug quality and efficacy consistency evaluation (Category 4 chemical drugs).

Vildagliptin is a selective, competitive, and reversible DPP-4 inhibitor used to lower blood sugar in patients with type 2 diabetes. It is not easy to induce hypoglycemia and has no effect on the patient's weight. After administration, vildagliptin can quickly inhibit DPP-4 activity, increase the levels of endogenous glucagon GLP-1 (glucagon polypeptide-1) and GIP (glucose-dependent insulinotropic polypeptide) in the fasting and postprandial state, thereby increasing the sensitivity of β-cells to glucose and promoting the secretion of glucose-dependent insulin. By increasing the level of endogenous GLP-1, vildagliptin can also increase the sensitivity of α-cells to glucose, thereby improving the fit between glucose levels and glucagon secretion. During hyperglycemia, vildagliptin increases incretin levels and the insulin/glucagon ratio, resulting in a decrease in fasting and postprandial liver glucose production, thereby lowering blood sugar, which is recommended by authoritative organizations and guideline consensus.

Vildagliptin tablets are the third oral hypoglycemic drug of Jiudian Pharmaceutical approved by NMPA after sitagliptin phosphate tablets and empagliflozin tablets. It further consolidates the company's market layout in the field of diabetes treatment, injects new vitality into the future development of Jiudian Pharmaceutical, and brings new market opportunities.